CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

NCT04510051 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Malignant Brain Neoplasm
Recurrent Malignant Brain Neoplasm
Refractory Malignant Brain Neoplasm

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

Sponsor

City of Hope Medical Center

Collaborators

[object Object]